Connect with us

Cannabis News

Is the DEA Still Worth It? Physician Calls for Rescheduling of Cannabis or Abolish the DEA!

Published

on


abolish the dea

Is the DEA still worth it? A Cost Benefit Analysis

 

In 1971, Richard Nixon signed the Controlled Substances Act into law, forever changing the landscape of drug regulation in the United States. This act didn’t just introduce a new set of rules regarding the use, manufacture, and distribution of certain substances; it also birthed the Drug Enforcement Administration (DEA), a body designated as the ‘judge, jury, and executioner’ of these newly established laws. With a stroke of a pen, a war on drugs was officially declared, and the DEA was enlisted as its chief warrior.

 

The DEA’s role was clear from the onset – to safeguard Americans from what was perceived as the scourge of drugs. Tasked with enforcing the Controlled Substances Act, this agency was given extensive power and authority to regulate drug use in the country. This included not just law enforcement duties but also the power to classify drugs, a role that placed them at the intersection of public health, politics, and law.

 

Fast forward several decades, and the DEA’s position has only solidified. A recent interaction with Congress highlighted this. Congressmen, recognizing the evolving perspective on cannabis, recommended the DEA consider descheduling the substance, a move that aligns with growing public sentiment and scientific understanding of cannabis. However, the DEA’s response was telling. They asserted their “final authority” in drug classification matters, a stance that underscores their autonomy and the centralized power structure they operate within.

‘Abolish The DEA’: Julie Holland, M.D., a psychiatrist, MDMA and cannabis researcher and medical advisor to the Multidisciplinary Association for Psychedelic Studies (MAPS), let her feelings be known about the recent decisions by the DEA.

“This will be the third time, if I’m not mistaken, that there will have been a recommendation to the DEA to make cannabis schedule 3. Twice they have refused. If they do it again, I will say it again: Abolish the DEA,” Holland wrote in a tweet. 

This interaction raises crucial questions about the role and effectiveness of the DEA. Are they operating in the best interests of public health and safety, or are their actions reflective of outdated, hardline policies? In a world where the understanding of substances like cannabis is rapidly evolving, does the DEA’s stance hinder or help the cause of public health and justice?

 

It’s time to critically assess the DEA’s track record. Have they truly safeguarded Americans from the dangers of drugs, or have their actions contributed to other societal harms? As we delve into this article, we will conduct a thorough performance review of the DEA since the inception of the Controlled Substances Act. The goal is to determine whether their approach has been effective or if it’s time to rethink and possibly dismantle this powerful agency.

 

 

Since its inception in 1971, the Drug Enforcement Administration (DEA) has been at the forefront of the United States’ war on drugs. However, an examination of drug trends over the past decades, using DEA’s own statistics and independent studies, reveals a concerning picture: despite the agency’s efforts, drug consumption, manufacturing, and dealing have not only persisted but, in many cases, increased.

 

One of the most telling indicators of the rise in drug availability is the DEA’s own data on drug seizures. Over the years, the quantities of drugs seized have grown exponentially. According to a comprehensive report by the National Institute on Drug Abuse, there has been a significant increase in the production and distribution of various controlled substances, including heroin, cocaine, and methamphetamine. This surge in seizures doesn’t necessarily point to the DEA’s effectiveness; instead, it suggests that the manufacturing and distribution of these substances have increased to levels so high that even enhanced enforcement efforts can only make a dent.

 

This increase in drug availability under the DEA’s watch correlates with the emergence of several drug epidemics. The crack epidemic of the 1980s and the ongoing opioid crisis are prime examples. These crises didn’t just represent a failure to stem the flow of drugs; they also exposed the inadequacies in addressing the root causes of drug abuse and the socio-economic factors that drive it.

 

Furthermore, the DEA’s approach often appears to be inconsistent and unbalanced. While significant resources have been expended in combating street-level drug dealing and targeting individual users, the same level of scrutiny and enforcement has not been consistently applied to pharmaceutical companies. These companies have played a significant role in the opioid epidemic through aggressive marketing and distribution of painkillers, much of which was done legally and under the DEA’s purview.

 

A stark example of the DEA’s misplaced priorities is its approach to cannabis. Despite a growing body of research indicating the medical benefits of marijuana and a shift in public opinion favoring its legalization, the DEA has continued to classify it as a Schedule I drug — the same category as heroin and LSD, reserved for substances with no currently accepted medical use and a high potential for abuse. Now, with psychedelic research well under way, even LSD and other hallucinogens in Schedule I is not accurate anymore.This classification has not only hindered research into the medical applications of cannabis but also led to the criminalization of individuals for possession and cultivation of a plant that many states have now legalized, either for medical or recreational use.

 

The DEA’s focus on punitive measures rather than harm reduction and prevention has also been questioned. Critics argue that the criminalization of drug use has led to overcrowded prisons, disproportionately affecting minority communities, without substantially reducing drug use or addiction rates.

 

The evidence suggests that the DEA has failed to significantly impact drug consumption and manufacturing. The rise in drug availability, the emergence of drug epidemics under their watch, and the inconsistent enforcement policies highlight the need for a reassessment of the DEA’s role and strategies in drug control. It raises the question: is it time to consider alternative approaches that prioritize public health, education, and rehabilitation over criminalization and punitive enforcement?

 

 

Rooted in the philosophy of prohibition, a concept that has repeatedly proven unsustainable and detrimental, the DEA continues to cling to outdated policies that not only fail to address the complexities of drug use and abuse but also actively harm communities and erode civil liberties.

 

Prohibition, as a policy, has a notorious history, with its most famous failure being the 1920s alcohol ban in the United States. This era was marked by a rise in organized crime, corruption, and a general disregard for the law. Despite these glaring issues, the DEA fails to recognize prohibition’s inherent flaws. Instead, they persist with a similar approach to controlled substances, creating a parallel to the past’s failures.

 

The DEA’s unwavering commitment to prohibition is not rooted in public health or safety but rather in self-preservation and a desire to maintain power. The agency has become a self-sustaining entity, benefiting from the very prohibition that fuels its existence. This cycle of enforcement and punishment has created a lucrative industry for the DEA, marked by significant budgets and expansive authority.

 

The impact of the DEA’s policies extends far beyond their intended scope, affecting communities and individuals in profound and often irreversible ways. The War on Drugs, spearheaded by the DEA, has disproportionately targeted minority communities, contributing to a cycle of poverty, criminalization, and disenfranchisement. This targeted enforcement has led to the mass incarceration of people of color, tearing families apart and exacerbating social inequalities.

 

Moreover, the DEA’s unilateral decision-making process poses a significant threat to the democratic principles upon which the United States was founded. The agency operates with little to no public oversight or participation, making decisions that affect millions without their input. This centralized power contradicts the ideals of democracy and transparency, leading to policies that often do not reflect the will or best interests of the people.

 

Continuing to fund and support the DEA means upholding the legacy of Harry Anslinger, a notoriously racist bureaucrat who played a key role in shaping America’s drug policy. Anslinger’s influence was marked by racial prejudice, power mongering, and deception, setting the stage for the punitive and discriminatory policies the DEA enforces today. By sustaining the DEA, we inadvertently endorse these outdated and harmful ideologies.

 

The DEA represents an archaic and harmful approach to drug policy, one that fails to adapt to modern understanding and societal needs. If we believe in the sanctity of the United States and its democratic principles, it is imperative to recognize the DEA as a relic of a bygone era, an agency that perpetuates the oppressive tactics of its predecessors. To truly liberate the people and uphold the values of justice and equality, it is necessary to exorcise the DEA and its antiquated, harmful policies. Only then can we begin to forge a path towards a more humane, effective, and just approach to drug regulation and control.

 

 

After more than half a century of stringent drug regulation, it’s evident that the war on drugs has been won, not by law enforcement agencies like the DEA, but by the drugs themselves. The Controlled Substances Act, which has been the cornerstone of this protracted battle, has not only failed to curb drug use and trafficking but has also exacerbated societal ills and infringed on individual liberties. The time has come for the United States, and indeed the world, to radically rethink its approach to drug regulation.

 

The DEA, despite its self-proclaimed final authority in drug classification, cannot continue to dictate an outdated and ineffective policy. The CSA and similar documents across the globe need to be abolished or profoundly reformed. We must acknowledge and respect the principle that individuals have the liberty to make choices about their own bodies, provided they do not harm others. This approach aligns with the core values of freedom and personal autonomy that are central to democratic societies.

 

A new paradigm for drug regulation should be adopted, one that prioritizes public health, education, and harm reduction over criminalization and punishment. Such a system would not only respect individual freedoms but also address the root causes of drug abuse, offering a more compassionate and effective solution to a challenge that has long plagued our society. The time for change is now; let’s embrace a future that upholds liberty, promotes well-being, and acknowledges the lessons of the past.

 

THE DEA AND CONGRESS ON CANNABIS RESCHEDULING, READ ON…

DEA VS CONGRESS OVER MARIJUANA RESCHEDULING

THE DEA AND CONGRESS TRADES BARBS OVER CANNABIS RESCHEDULING!



Source link

Cannabis News

The US Suddenly Has Two Pro-Marijuana Legalization Candidates, But Only One is Believable 60 Days Before the Election

Published

on

By


Trump and Harris both support cannabis legalization

“Don’t Believe the Hype” – Public Enemy

In a surprising move, former President Donald Trump has publicly endorsed the legalization of cannabis, arguing that the criminalization of marijuana “ruins lives” and “wastes taxpayer dollars.” Speaking at a rally in Florida, Trump expressed confidence that voters will support a marijuana legalization initiative on the November ballot, stating, “I really believe it’s the right thing to do.”

Trump’s comments come at a time when public support for cannabis legalization is at an all-time high, with recent surveys indicating that approximately 78% of American adults favor legalization. The economic implications of this shift are significant, with the cannabis industry currently employing around 500,000 people and generating $29 billion in sales last year, a figure projected to rise to $37 billion by 2027.

The Harris camp immediately accussed the Trump camp of a “brazen flip-flop” on marijuana legalization just before the election in order ot try and lure swing voters. Based on Trump’s past presidency and his work with Attorney General Sessions during his first term, he is certainly no fan of marijuana, marijuana legalization, or was in any rush to support states that establisted legal, medical cannabis programs.  As they say in life, “watch what someone does, not what they say 60 days before an election”, Trump had his chance as Commander-In-Chef and put the marijuana movement back 5 steps when he was in office.

This certainly smells fishy from the start based on his track record on drugs, alcohol, and marijuana legalization. Remember, he actually took steps in his Presidency to shut the marijuana movement down in America according to the New York Times.

 

Harris, on the other hand, claims to be for rescheduling cannabis and even legalizatio,n and a large clemency program. While she has been Vice-President for 4 years and legalization has not happened, her boss, President Biden, is no fan of drugs and has been on a founding memeber of the “War on Drugs” for over 40 years in office.  So no, Harris has not “had her chance” the way Trump has had his chance as the actual President. As many know, the Vice-President’s roll in some instances is more for show and to take tours and visits the president does not have time or want to to do. 

 

Harris has a “yet to be determined, yet things look good” on her marijuana legalization report card.

 

As MJBIZ covered in their artice on who would be better for marijuana reform going forward..

During a relatively quiet few years as vice president, Harris stumped for Biden’s generational advances in marijuana reform.

She was out front on the Biden administration’s pardons for former federal marijuana offenders as well as the October 2022 executive order that culminated in the Justice Department’s proposal this spring to move marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act.

“She’s actually gone further than (Biden),” said Bryan Barash, vice president of external affairs and deputy general counsel at Dutchie, an Oregon-based online cannabis sales platform.

“She’s said, ‘We can’t stop until there’s full legalization,’ which he has never said.”

In other words, Harris has the best record on marijuana reform of any major presidential candidate, including Biden.

 

Economic Implications of Legalization

 

The economic implications of cannabis legalization are substantial. The cannabis industry has rapidly evolved into a multi-billion dollar market, employing around 500,000 people and generating $29 billion in sales in the past year alone. Projections indicate that this figure could rise to $37 billion by 2027, highlighting the potential for job creation and economic growth in states that choose to legalize cannabis.

 

  • Job creation: Legalizing cannabis could create thousands of jobs across various sectors, significantly boosting the economy. In agriculture, the cultivation of cannabis will require a workforce for planting, harvesting, and processing. The retail sector will also expand, as dispensaries will need staff for sales and management roles. Additionally, manufacturing jobs will emerge to produce cannabis-infused products, such as edibles and oils. Overall, legalization can lead to substantial job creation in agriculture, retail, and manufacturing, benefiting local communities and economies.

 

  • Tax Revenue: Legalizing cannabis could create thousands of jobs across various sectors, providing a significant boost to the economy. In agriculture, the cultivation of cannabis will require workers for planting and harvesting. The retail sector will also expand, as dispensaries will need staff for sales and management roles. Additionally, manufacturing jobs will emerge to produce cannabis-infused products like edibles and oils. Overall, legalization can lead to substantial job creation, benefiting local communities and economies.

 

 

  • Economic Growth:  A legal cannabis market has the potential to stimulate economic growth, especially in economically disadvantaged areas. By establishing regulated cannabis businesses, communities can attract investment and create new revenue streams, leading to job creation and increased local spending. This influx of economic activity can revitalize struggling neighborhoods, providing opportunities for entrepreneurship and supporting ancillary businesses, such as suppliers and service providers. Additionally, the tax revenue generated from cannabis sales can be reinvested into public services, infrastructure, and community development projects, further enhancing the overall economic landscape. Ultimately, legalizing cannabis can serve as a catalyst for sustainable growth and revitalization in areas that need it most

 

 Health Benefits and Opioid Reduction

 

Trump also emphasized the health advantages of legal cannabis, particularly its potential role in managing chronic pain and reducing reliance on opioids. This point is especially relevant given the ongoing opioid epidemic, which has claimed hundreds of thousands of lives in recent years.

 

 

 

  • Mental Health Benefits: Emerging research suggests that cannabis may also have therapeutic benefits for mental health conditions, such as anxiety and depression, further supporting its legalization.

 

Disproportionate Impact on Communities of Color

Trump’s advocacy for cannabis legalization also reflects a growing awareness of the disproportionate impact of cannabis criminalization on communities of color. Over 40,000 individuals remain incarcerated for non-violent cannabis offenses, with Black and Hispanic individuals being significantly more likely to face prosecution and harsher sentences for cannabis-related crimes.

 

 

  • Social Equity Programs: Many states that have legalized cannabis have implemented social equity programs aimed at helping communities disproportionately affected by the War on Drugs, providing opportunities for entrepreneurship and economic participation in the legal cannabis market.

 

  • Expungement of Records: Legalization efforts often include provisions for expunging the records of individuals previously convicted of non-violent cannabis offenses, allowing them to reintegrate into society without the stigma of a criminal record.

 

Shifting Political Landscape

 

Trump’s endorsement of cannabis legalization represents a significant shift in the political discourse surrounding the issue. Historically, the Republican Party has been more resistant to legalization efforts, with many conservatives expressing concerns about the potential for increased drug use and public safety risks. However, as public opinion has shifted and the economic and social benefits of legalization have become more apparent, some Republican leaders have begun to reconsider their stance.

 

 

  • Influence of State-Level Legalization: The success of state-level legalization efforts has provided a blueprint for national policy changes, demonstrating that cannabis can be regulated effectively without compromising public safety.

 

Potential Impact on the 2024 Election

Trump’s support for cannabis legalization could have significant implications for the 2024 presidential election, particularly if he decides to run again. By aligning himself with a popular issue that enjoys broad bipartisan support, Trump may be able to attract a wider range of voters, including younger and more progressive-leaning individuals who have traditionally been skeptical of Republican candidates.

 

  • Engaging Younger Voters: Younger voters, who are more likely to support cannabis legalization, could be crucial for Trump’s campaign, potentially swaying their votes in his favor.

  • Broadening the Republican Base: By embracing cannabis legalization, Trump may be able to broaden the Republican base and attract independent voters who prioritize social justice and economic reform.

 

 

Conclusion

Donald Trump’s endorsement of cannabis legalization marks a significant milestone in the ongoing effort to end the criminalization of marijuana in the United States. By acknowledging the negative impact of prohibition on individuals, communities, and taxpayers, and highlighting the potential benefits of legalization, Trump is adding his voice to a growing chorus of advocates who believe that it is time for a new approach to cannabis policy. As the 2024 election cycle approaches, it will be fascinating to observe how Trump’s stance on this issue shapes the political landscape and influences the debate over the future of cannabis in America. With public support at an all-time high and the economic and social benefits becoming increasingly clear, the momentum for cannabis legalization appears poised to continue growing in the years to come.

 

TRUMP FOR 4 MORE YEARS BUT YOU GET CANNABIS LEGALIZATION, YES OR NO? SEE BELOW!

TRUMP IF HE LEGALIZED WEED, YES OR NO

WOULD YOU TAKE TRUMP FOR 4 YEARS IF HE LEGALIZED WEED?



Source link

Continue Reading

Cannabis News

What State Just Dropped Below $80 an Ounce for Legal Cannabis? A. Florida B. Michigan C. California D. New York

Published

on

By


cannabis price drops michigan

In a significant development for Michigan’s cannabis industry, retail prices have fallen below $80 per ounce as of September 4, 2024. This historic milestone, reflecting a nearly 14.5% decline from the previous year, signals a major shift in market dynamics.

The price drop is driven by increased competition among licensed dispensaries, a growing supply of cannabis products, and the maturation of the market since the legalization of recreational use in 2018. More dispensaries and cultivation facilities have led to competitive pricing and greater product availability, making cannabis more affordable for consumers and potentially boosting legal sales.

As a leader in the Midwest’s cannabis landscape, Michigan’s regulatory framework supports both medical and recreational markets, generating significant tax revenue and job opportunities. As the industry evolves, stakeholders must navigate challenges and capitalize on emerging opportunities.

 

Factors Behind the Price Drop

The surge in the number of licensed dispensaries in Michigan since the legalization of recreational cannabis in 2018, coupled with the expansion of cultivation facilities, has led to a significant increase in the supply and availability of cannabis products. With more dispensaries offering a wider variety of choices for consumers, the market has become increasingly competitive, with retailers employing pricing strategies to attract customers. This growth in the number of dispensaries and cultivation facilities has enabled dispensaries to offer lower prices to consumers, making cannabis more accessible and affordable.

 

As the cannabis market matures, both producers and retailers have optimized their operations, leading to reduced costs that are often passed on to consumers. Enhanced cultivation techniques and economies of scale have played a crucial role in lowering production expenses, allowing businesses to improve efficiency and increase output. This combination of operational optimization and cost reduction not only benefits producers and retailers but also makes cannabis products more affordable and accessible for consumers, fostering a healthier and more competitive market environment.

The market has become oversaturated with cannabis products, particularly following significant outdoor harvests. This oversupply has led to a decrease in prices as producers and retailers compete to sell excess inventory.

Michigan currently has no statewide cap on the number of cannabis business licenses, resulting in explosive growth in both supply and demand. This unrestricted licensing has intensified competition among businesses, driving prices downward as they vie for market share.

 

 Implications for Consumers and the Industry

The recent drop in cannabis prices has made the product more affordable for a broader segment of the population, enabling consumers to access quality cannabis without financial strain. This increased affordability not only allows more individuals to enjoy legal cannabis but also promotes responsible use and consumption, as people are more likely to make informed choices when quality products are within reach. By removing financial barriers, the industry is fostering a healthier relationship with cannabis among consumers, contributing to a more informed and responsible market.

 

The potential boost in sales volume is another significant implication of the lower cannabis prices in Michigan. As the cost of cannabis becomes more affordable, more consumers are likely to enter the market, leading to an increase in overall sales. Dispensaries may experience higher foot traffic as a result of this increased interest in cannabis products, directly benefiting from the lower prices. This influx of new consumers and higher sales volume could further solidify the industry’s growth and sustainability in the state, as businesses capitalize on the greater demand for their products.

The competitive pricing of legal cannabis products in Michigan has the potential to curb illegal sales by making regulated options more attractive to consumers. As the cost of legal cannabis becomes more affordable and accessible, individuals may be more inclined to purchase from licensed dispensaries rather than the black market. This shift towards regulated products not only supports the legal industry but also enhances public safety and quality assurance. By choosing legal cannabis, consumers can be confident in the safety, purity, and potency of the products they purchase, reducing the risks associated with unregulated, illicit markets. As more consumers opt for legal cannabis due to the competitive pricing, the state can expect to see a decline in illegal sales and an improvement in overall public health and safety.

 

Michigan’s Cannabis Landscape

 

Since the legalization of recreational cannabis in Michigan, the state has become a pioneer in cannabis reform within the Midwest. With a comprehensive regulatory framework in place, Michigan supports both medical and recreational markets, fostering a thriving industry that has generated significant tax revenue and job opportunities.

 

The cannabis industry in Michigan has significantly contributed millions in tax revenue, which is allocated to vital areas such as education, infrastructure, and public health initiatives. Additionally, the industry’s growth has led to job creation across cultivation, distribution, and retail sectors, providing numerous employment opportunities for residents. This dual impact not only supports the state’s economy but also enhances community well-being through improved public services and increased job availability.-

As cannabis prices continue to decrease in Michigan, making the products more accessible to a wider consumer base, there is a growing need for comprehensive consumer education. Dispensaries are increasingly taking on the responsibility of educating their customers on responsible use, product selection, and the effects of various cannabis strains. By offering workshops and informational resources, dispensaries aim to help consumers make informed choices and develop a deeper understanding of the products they consume. This proactive approach to consumer education not only promotes responsible use but also fosters a more informed and engaged cannabis community in the state.

 

Conclusion

The decline in cannabis prices to below $80 per ounce is a significant development for Michigan, highlighting the success of Its regulatory framework and the positive impact on consumers. As the market matures, stakeholders will need to remain vigilant in addressing challenges while capitalizing on the opportunities presented by this dynamic industry.

 

MICHIGAN CANNABIS PRICES PLUMMET, READ ON…

MICHICAN CANNABIS FLOWER PRICES

MICHIGAN CANNABIS FLOWER PRICES DROP BELOW $122, IS $80 NEXT?



Source link

Continue Reading

Cannabis News

Loper Comes for the DEA. Will it Matter, Though?

Published

on

By


Earlier this week, the federal Fourth Circuit Court of Appeals, in a case entitled Anderson v. Diamondback Investment Group, LLC, handed the DEA a big loss when it comes to hemp – at least for now. In Anderson, the court held that DEA’s interpretation that a host of hemp-derived products were illegal was essentially wrong. Today I want to talk about why Anderson is – and isn’t really – important.

Anderson, as I wrote more than a month ago, was based in relevant part on Loper Bright Enterprises v. Raimondo, a 2024 US Supreme Court decision. Here’s what I said then:

Loper ended what’s often referred to as “Chevron deference.” To vastly oversimplify, Chevron deference required federal courts to defer to reasonable agency interpretations of ambiguous statutes, even if courts did not agree with those interpretations. With Chevron dead, courts will not be required to defer to agencies and courts can decide, on their own, whether an agency’s interpretation was within its statutory authority.

Ever since Loper was decided, there have been a million different theories on how it could affect the cannabis and hemp industries. [For the record, I agree with folks like Shane Pennington who argue that Loper will not affect rescheduling.]

When it comes to hemp though, Loper may in theory have more of an impact, as my colleague, Vince Sliwoski, argued prior to Loper‘s publication. That’s because the DEA routinely issues what amount to opinion letters as to whether this or that cannabinoid is or is not a schedule I narcotic. Under Loper, if there were any statutory ambiguity, the DEA’s interpretation would no longer be given deference. That’s not to say that the DEA might not prevail, but it means the deck would be less stacked in DEA’s favor.

And that is essentially what happened in Anderson. Without getting into the factual weeds of the case, an employee had been terminated after drug tests allegedly showed marijuana use. She sued, in part claiming that she used legal hemp-derived products. The court ultimately held that she had failed to provide they were legal because she did not introduce sufficient evidence that the hemp products had less than 0.3% delta-9 THC.

However, for purposes of this post, the important part of the Anderson decision was its discussion of the 2018 Farm Bill and DEA’s interpretations of the legality of various cannabinoids under that law. One specific cannabinoid that the court analyzed was THC-O, which does not occur naturally but is created from hemp derivatives.

For years, there has been a heated debate as to whether hemp-derived products like delta-8 THC are considered “hemp” under the 2018 Farm Bill. The debate centers around whether these products are “synthetic” because they are derived from other cannabinoids. This is important because DEA considers synthetic cannabinoids to be controlled substances.

A few years ago, in AK Futures LLC v. Boyd Street Distro, LLC, the Ninth Circuit Court of Appeals addressed the issue (albeit in a much different context), and held that delta-8 THC products derived from hemp with less than 0.3% THC were legal under the 2018 Farm Bill.

Importantly, Anderson found AK Futures persuasive, holding:

“we think the Ninth Circuit’s interpretation of the 2018 Farm Act is the better of the two. And we’re free to make that determination ourselves, despite a contrary interpretation from the DEA, because we agree with the Ninth Circuit that [the 2018 Farm Bill’s definition of hemp] is unambiguous . . ., and because even if it were ambiguous, we needn’t defer to the agency’s interpretation [as a result of the Loper decision].”

Crucially, Anderson held that “rather than originating from organic matter—like the hemp-derived cannabinoids at issue—, synthetic cannabinoids are just that: compounds manufactured entirely out of synthetic materials.”

To summarize all of this, according to the Fourth Circuit, if a product is derived from hemp and does not contain more than 0.3% THC, it is legal. This includes things pulled directly from the plant, or things like delta-8 THC which may take other processes to produce. But, any cannabinoid derived purely from synthetic materials would not be considered “hemp” under the 2018 Farm Bill.

All of that said, Anderson probably won’t matter much. As I noted in in July:

[A]ll of [the discussion about Loper] is almost certainly academic – at least if Congress passes the Farm Bill with proposed amendments that would ban intoxicating hemp products. If that happens, the DEA won’t need to opine on the legality of many (if not most or all) intoxicating hemp products. The law would have already changed to prohibit them expressly.

But what happens if the upcoming Farm Bill doesn’t contain bans on intoxicating hemp products? Things will almost certainly not end there. The FDA, which has been hostile to many hemp products since the day the 2018 Farm Bill was passed, could simply claim products are adulterated or misbranded and seek to pull them from the market. It does this with kratom, which is an unscheduled plant, and there’s no reason why it could not do it here (subject again to FDA having to prove its case in a post-Loper court challenge).

And, as I noted, federal law isn’t the only thing that matters:

Things are also not looking great for intoxicating hemp products at the state and local levels. The State of Virginia, for example, just levied nearly $11 million in fines against more than 300 retailers allegedly selling state-prohibited intoxicating hemp products. Out west, the Colorado attorney general sued a business in June for allegedly selling super-high THC products marketed as federally legal hemp.

We also assume that there is a lot of local enforcement actions that go under the radar – things like state or local public health officials pulling products from shelves or warning stores. That can be harder to track if for no other reason than it doesn’t often make the news. We also assume that a lot of the reports concerning enforcement against alleged illegal marijuana stores or operators, including in places like New York, may miss the legal nuances between intoxicating hemp products and illegal cannabis products.

In sum, the intoxicating cannabinoid industry just won the battle with DEA, but it’s probably not going to win the war.



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media